Clinical Trial: Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549698) titled 'Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease' on April 08.

Brief Summary: This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Warm Autoimmune Hemolytic Anemia (WAIHA) ITP - Immune Thrombocytopenia Warm Autoimmune ...